TY - JOUR
T1 - Plasma adipokines and glycaemic progression among African Americans
T2 - Findings from the Jackson Heart Study
AU - Kaze, Arnaud D.
AU - Musani, Solomon K.
AU - Bidulescu, Aurelian
AU - Joseph, Joshua J.
AU - Correa, Adolfo
AU - Ndumele, Chiadi E.
AU - Bertoni, Alain G.
AU - Ahima, Rexford S.
AU - Golden, Sherita H.
AU - Echouffo-Tcheugui, Justin B.
N1 - Publisher Copyright:
© 2020 Diabetes UK
PY - 2021/5
Y1 - 2021/5
N2 - Aim: To evaluate the association between plasma biomarkers including leptin, adiponectin, adiponectin-to-leptin ratio and high-sensitivity C-reactive protein (hsCRP) with risk of glycaemic progression and incident dysglycaemia (pre-diabetes or diabetes) in a community-based sample of African American (AAs). Methods: We analysed data from 3223 participants without type 2 diabetes at baseline (2000–2004) who attended ≥1 follow-up visit. Poisson regression was used to generate risk ratios (RRs) for glycaemic progression and incident dysglycaemia. Results: Over a median of 7 years, 46.4% developed glycaemic progression (n=1495). After adjusting for demographic and lifestyle variables, the RRs (95% CI) for glycaemic progression comparing highest (Q4) to lowest (Q1) quartiles were 1.30 (1.10–1.54), 0.74 (0.65–0.84), 0.70 (0.62–0.80) and 1.22 (1.07–1.38) for leptin, adiponectin, adiponectin–leptin ratio and hsCRP, respectively. Upon additional adjustment for BMI, the corresponding RRs (95% CIs) were 1.15 (0.94–1.42), 0.76 (0.67–0.86), 0.72 (0.62–0.84) and 1.14 (0.99–1.31) respectively. Among participants with normal glycaemia, the RRs (95% CIs) for incident pre-diabetes in Q4 vs Q1 were 1.37 (1.13–1.67), 0.73 (0.63–0.85), 0.70 (0.59–0.82) and 1.28 (1.10–1.48) for leptin, adiponectin, adiponectin–leptin ratio and hsCRP, respectively; equivalent RRs for incident diabetes were 5.15 (2.63–10.10), 0.36 (0.20–0.68), 0.21 (0.12–0.38) and 3.04 (1.70–5.44), respectively. Conclusions: In this large community-based cohort of AAs, our results suggest that high plasma leptin and hsCRP, as well as low adiponectin and adiponectin-to-leptin ratio, are associated with higher risks of glycaemic progression. The findings point to the potential utility of these biomarkers in predicting and preventing glycaemic progression in this high-risk population.
AB - Aim: To evaluate the association between plasma biomarkers including leptin, adiponectin, adiponectin-to-leptin ratio and high-sensitivity C-reactive protein (hsCRP) with risk of glycaemic progression and incident dysglycaemia (pre-diabetes or diabetes) in a community-based sample of African American (AAs). Methods: We analysed data from 3223 participants without type 2 diabetes at baseline (2000–2004) who attended ≥1 follow-up visit. Poisson regression was used to generate risk ratios (RRs) for glycaemic progression and incident dysglycaemia. Results: Over a median of 7 years, 46.4% developed glycaemic progression (n=1495). After adjusting for demographic and lifestyle variables, the RRs (95% CI) for glycaemic progression comparing highest (Q4) to lowest (Q1) quartiles were 1.30 (1.10–1.54), 0.74 (0.65–0.84), 0.70 (0.62–0.80) and 1.22 (1.07–1.38) for leptin, adiponectin, adiponectin–leptin ratio and hsCRP, respectively. Upon additional adjustment for BMI, the corresponding RRs (95% CIs) were 1.15 (0.94–1.42), 0.76 (0.67–0.86), 0.72 (0.62–0.84) and 1.14 (0.99–1.31) respectively. Among participants with normal glycaemia, the RRs (95% CIs) for incident pre-diabetes in Q4 vs Q1 were 1.37 (1.13–1.67), 0.73 (0.63–0.85), 0.70 (0.59–0.82) and 1.28 (1.10–1.48) for leptin, adiponectin, adiponectin–leptin ratio and hsCRP, respectively; equivalent RRs for incident diabetes were 5.15 (2.63–10.10), 0.36 (0.20–0.68), 0.21 (0.12–0.38) and 3.04 (1.70–5.44), respectively. Conclusions: In this large community-based cohort of AAs, our results suggest that high plasma leptin and hsCRP, as well as low adiponectin and adiponectin-to-leptin ratio, are associated with higher risks of glycaemic progression. The findings point to the potential utility of these biomarkers in predicting and preventing glycaemic progression in this high-risk population.
KW - Adipokines
KW - blacks
KW - dysglycaemia
UR - http://www.scopus.com/inward/record.url?scp=85098089839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098089839&partnerID=8YFLogxK
U2 - 10.1111/dme.14465
DO - 10.1111/dme.14465
M3 - Article
C2 - 33236370
AN - SCOPUS:85098089839
SN - 0742-3071
VL - 38
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 5
M1 - e14465
ER -